Product
GP2411
1 clinical trial
1 indication
Indication
Postmenopausal Women With OsteoporosisClinical trial
A Randomized, Double-blind, Multicenter Integrated Phase I/III Study in Postmenopausal Women With Osteoporosis to Compare the Pharmacokinetics, Pharmacodynamics, Efficacy, Safety and Immunogenicity of GP2411 (Proposed Biosimilar Denosumab) and Prolia® (EU-authorized)Status: Completed, Estimated PCD: 2022-04-22